Activation of the innate immune system and vascular inflammation in patients with type 1 diabetes mellitus - Activation innate immune system in type 1 diabetes

Radboud Universitair Medisch Centrum0 个研究点目标入组 60 人开始时间: 待定最近更新: 2024年2月28日

适应症

试验速览

暂无简介。

•Group 1: Type 1 diabetes, HbA1c > 64 mmol/mol; Group 2: Type 1 diabetes, HbA1c <64 mmol/l; Group 3: Healthy controls.
•Group 1 and 2: type 1 diabetes, diagnosis based on clinical data, duration of diabetes *10 years, age *20 years, * 60 years, written informed consent
•Group 3: absence of disease; matched for age,, gender and BMI; HbA1c <42 mmol/mol; written informed consent

•- Inability to provide informed consent
•- Specific Medication use:
•o Use of immunosuppressive drugs
•o Use of statins < 2 weeks before performing PET-CT (Those that use statins will be asked to discontinue for two weeks. This can be safely done in the context of primary prevention.)
•o Use of acetylsalicylic acid
•- Previous cardiovascular events (ischemic stroke/TIA, myocardial infarction, peripheral arterial disease)
•- Auto-inflammatory or auto-immune diseases
•- Current or recent infection (< 3 months)
•- Previous vaccination (< 3 months)
•- Renal failure (MDRD <45)
•- BMI>30 kg/m2
•- Pregnancy
•- Claustrophobia
•- Severe hypoglycaemia < 1 week before PET-CT

发起方